|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/15/23 TRxADE HEALTH, Inc. 8-K:3,5,9 6/15/23 11:247K M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 72K 2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 11K 6: R1 Cover HTML 47K 9: XML IDEA XML File -- Filing Summary XML 12K 7: XML XBRL Instance -- form8-k_htm XML 15K 8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB XBRL Labels -- meds-20230615_lab XML 96K 5: EX-101.PRE XBRL Presentations -- meds-20230615_pre XML 64K 3: EX-101.SCH XBRL Schema -- meds-20230615 XSD 12K 10: JSON XBRL Instance as JSON Data -- MetaLinks 25± 34K 11: ZIP XBRL Zipped Folder -- 0001493152-23-021489-xbrl Zip 21K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): i June 15, 2023
(Exact name of registrant as specified in its charter)
| i Delaware | i 001-39199 | i 46-3673928 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| i 2420 Brunello Trace, i Lutz, i Florida | i 33558 | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||
| i Common Stock, par value $0.00001 per share | i MEDS | i The Nasdaq Stock Market LLC (Nasdaq Capital |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.03. Material Modifications to Rights of Security Holders
As described in Item 5.03 below, the stockholders of the TRxADE HEALTH, INC. (the “Company”) authorized the Board of Directors of the Company in its sole and absolute discretion, and without further action of the stockholders, to file a Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) at the annual meeting of the stockholders of TRxADE Health Inc. (the “2023 Annual Meeting”).
Item 5.03. Articles of Incorporation or Bylaws
The stockholders of the Company authorized the Board of Directors of the Company in its sole and absolute discretion, and without further action of the stockholders, to file a Certificate of Amendment at the 2023 Annual Meeting, which amends and restates subsection 3 of Article V (Reverse Stock Split of Outstanding Common Stock) to effect a reverse split of the Company’s issued and outstanding common stock, par value $0.00001 per share, at a ratio to be determined by the Board, ranging from one-for-ten to one-for-one hundred (the “Reverse Split”), with the Reverse Split to be effected at such time and date, if at all, as determined by the Board in its sole discretion, but no later than December 31, 2023, when the authority granted by the stockholders of the Company to implement the Reverse Split would terminate.
Item 5.07. Submission of Matters to a Vote of Security Holders
On June 15, 2023, the Company held its 2023 Annual Meeting to consider Proposals 1 through 4 as described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on May 5, 2023 (the “Proxy Statement”). A summary of the matters voted upon by stockholders is set forth below.
Proposal 1—Reverse Stock Split
The Company’s stockholders approved a proposal to authorize the board of directors of the Company (the “Board”), in its sole and absolute discretion, and without further action of the stockholders, to file an amendment to the Company’s Certificate of Incorporation, as amended to the date of the Proxy Statement, to effect a reverse stock split of the Company’s issued and outstanding common stock at a ratio to be determined by the Board, ranging from one-for-ten to one-for-one hundred, with such reverse stock split to be effected at such time and date, if at all, as determined by the Board in its sole discretion, but no later than December 31, 2023. The following votes were taken in connection with this proposal:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | ||||||||||||||||||||||||||
| Number | % | Number | % | Number | % | Number | % | ||||||||||||||||||||||
| 5,327,981 | 52.18 | 88,393 | 0.87 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Proposal 2—Amendment of the Second Amended and Restated 2019 Equity Incentive Plan
The Company’s stockholders approved a proposal to amend the Company’s Second Amended and Restated 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 2,000,000 shares. The following votes were taken in connection with this proposal:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | ||||||||||||||||||||||||||
| Number | % | Number | % | Number | % | Number | % | ||||||||||||||||||||||
| 5,273,753 | 51.65 | 142, 621 | 1.40 | 0 | 0 | 0 | 0 | ||||||||||||||||||||||
Proposal 3—Election of Directors
The following individuals, constituting all of the nominees named in the Proxy Statement, were elected as directors to serve until the 2024 annual meeting of stockholders and until their successors have been duly elected and qualified. The following votes were taken in connection with this proposal:
| FOR | WITHHELD | |||||||||||||||
| Nominee | Number | % | Number | % | ||||||||||||
| Suren Ajjarapu | 5,411,101 | 53 | 5,273 | 0.05 | ||||||||||||
| Prashant Patel | 5,404,997 | 52.94 | 11,377 | 0.11 | ||||||||||||
| Donald G. Fell | 5,349,507 | 52.4 | 66,867 | 0.65 | ||||||||||||
| Michael L. Peterson | 5,387,936 | 52.77 | 28,438 | 0.28 | ||||||||||||
| Jeff Newell | 5,411,191 | 53 | 5,273 | 0.05 | ||||||||||||
Proposal 4—Ratification of Appointment of MaloneBailey LLP as Independent Auditor
The Company’s stockholders approved a proposal to ratify the appointment of MaloneBailey LLP as our independent auditor for the fiscal year ending December 31, 2023. The following votes were taken in connection with this proposal:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | ||||||||||||||||||||||||||
| Number | % | Number | % | Number | % | Number | % | ||||||||||||||||||||||
| 5,341,101 | 52.31 | 1,673 | 0.02 | 73,600 | 0.72 | 0 | 0 | ||||||||||||||||||||||
Item 9.01. Financial Statements and Exhibits
| Exhibit No. | Description of Exhibit | |
| 3.1 | Form of Certificate of Amendment to Second Amended and Restated Certificate of Incorporation | |
| 104 | Inline XBRL for the cover page of this Current Report on Form 8-K |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRxADE HEALTH, INC. | ||
| By: | /s/ Suren Ajjarapu | |
| Name: | Suren Ajjarapu | |
| Title: | Chief Executive Officer | |
| Dated: June 15, 2023 | ||
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/23 | None on these Dates | |||
| Filed on / For Period end: | 6/15/23 | |||
| 5/5/23 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/03/24 TRxADE HEALTH, Inc. 10-K/A 12/31/23 13:798K M2 Compliance LLC/FA 4/22/24 TRxADE HEALTH, Inc. 10-K 12/31/23 94:12M M2 Compliance LLC/FA 8/18/23 TRxADE HEALTH, Inc. 10-Q 6/30/23 59:4.8M M2 Compliance LLC/FA |